Brief: Sanofi's Cenrifki Approved In The EU For Secondary Progressive Multiple Sclerosis Without Relapses

Sanofi SA

23/06/2026 06:04

June 23 (Reuters) - Sanofi SA SASY.PA:
CENRIFKI (TOLEBRUTINIB) APPROVED IN THE EU AS THE FIRST DISABILITY-TARGETING MEDICINE FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS WITHOUT RELAPSES
APPROVAL BASED ON HERCULES PHASE 3 STUDY IN NRSPMS WITH SUPPORTING DATA FROM GEMINI 1 AND 2 PHASE 3 STUDIES IN RMS
WILL MAKE CENRIFKI COMMERCIALLY AVAILABLE IN GERMANY THIS YEAR
Source text: ID:nGNX14pRKk
Further company coverage: SASY.PA

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;;))